Chronic disease – Boston Strategic Partners, Inc.

TSI assay utilization: impact on costs of Graves’ hyperthyroidism diagnosis

McKee A, Peyerl F. TSI assay utilization: impact on costs of Graves’ hyperthyroidism diagnosis. Am J Manag Care. 2012;18(1):e1-14. View article

Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment

Posted by katarinachin in Publications

Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm. 2007;13(5):397-411. doi:10.18553/jmcp.2007.13.5.397. View Article